Table 2 Comparison of RCTs accessing RCHD with trials evaluated by the HRA in 2015
RCTs accessing RCHD (n = 160) | HRA in 2015a (n = 963b) | |
|---|---|---|
Recruitment setting | ||
Primary care | 41 (26%) | 48 (5%) |
Secondary care | 119 (74%) | 846 (95%) |
Unclear/missing | 0 | 69 |
Therapeutic area | ||
Cancer | 47 (29%) | 168 (17%) |
Cardiovascular and stroke | 46 (29%) | 121 (13%) |
Pregnancy and childbirth | 9 (6%) | 30 (3%) |
Infection | 8 (5%) | 55 (6%) |
Inflammatory disorder | 5 (3%) | 72 (7%) |
Drug trial | 76 (48%) | 515 (53%) |
Randomisation | ||
Individual | 136 (85%) | 934 (97%) |
Cluster trial | 24 (15%) | 29 (3%) |
Feasibility/pilot | 17 (11%) | 177 (18%) |
Sample size (median, range) | 1590 (41–6,000,000) | 275 (6–30,000) |
Unclear/missing | 0 | 440 |
Recruitment location | ||
UK only | 125 (78%) | 450 (50%) |
International trials | 32 (20%) | 443 (50%) |
Unclear/missing | 0 | 70 |